Logo image of NVCT

NUVECTIS PHARMA INC (NVCT) Stock Fundamental Analysis

NASDAQ:NVCT - US67080T1088 - Common Stock

6.78 USD
+0.29 (+4.47%)
Last: 8/26/2025, 3:26:56 PM
Fundamental Rating

2

Taking everything into account, NVCT scores 2 out of 10 in our fundamental rating. NVCT was compared to 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NVCT as it has an excellent financial health rating, but there are worries on the profitability. NVCT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NVCT has reported negative net income.
In the past year NVCT has reported a negative cash flow from operations.
NVCT had negative earnings in each of the past 5 years.
In the past 5 years NVCT always reported negative operating cash flow.
NVCT Yearly Net Income VS EBIT VS OCF VS FCFNVCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

NVCT has a worse Return On Assets (-81.71%) than 68.92% of its industry peers.
NVCT has a Return On Equity (-130.79%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -81.71%
ROE -130.79%
ROIC N/A
ROA(3y)-103.89%
ROA(5y)N/A
ROE(3y)-170.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVCT Yearly ROA, ROE, ROICNVCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NVCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVCT Yearly Profit, Operating, Gross MarginsNVCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NVCT has more shares outstanding
NVCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NVCT Yearly Shares OutstandingNVCT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
NVCT Yearly Total Debt VS Total AssetsNVCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

An Altman-Z score of 3.32 indicates that NVCT is not in any danger for bankruptcy at the moment.
The Altman-Z score of NVCT (3.32) is better than 74.04% of its industry peers.
There is no outstanding debt for NVCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.32
ROIC/WACCN/A
WACCN/A
NVCT Yearly LT Debt VS Equity VS FCFNVCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 2.66 indicates that NVCT has no problem at all paying its short term obligations.
NVCT has a Current ratio of 2.66. This is in the lower half of the industry: NVCT underperforms 67.46% of its industry peers.
A Quick Ratio of 2.66 indicates that NVCT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.66, NVCT is doing worse than 65.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
NVCT Yearly Current Assets VS Current LiabilitesNVCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

NVCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.30%, which is quite good.
EPS 1Y (TTM)9.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NVCT is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.51% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.82%
EPS Next 2Y2.98%
EPS Next 3Y-0.51%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVCT Yearly EPS VS EstimatesNVCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NVCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NVCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCT Price Earnings VS Forward Price EarningsNVCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCT Per share dataNVCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.98%
EPS Next 3Y-0.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVECTIS PHARMA INC

NASDAQ:NVCT (8/26/2025, 3:26:56 PM)

6.78

+0.29 (+4.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)N/A N/A
Inst Owners10.19%
Inst Owner Change57.78%
Ins Owners46.91%
Ins Owner Change1.21%
Market Cap172.62M
Analysts81.82
Price Target18.53 (173.3%)
Short Float %8.48%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.78%
Min EPS beat(2)-15.34%
Max EPS beat(2)-4.21%
EPS beat(4)1
Avg EPS beat(4)-13.08%
Min EPS beat(4)-39.5%
Max EPS beat(4)6.75%
EPS beat(8)3
Avg EPS beat(8)-3.53%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.39%
PT rev (3m)5.31%
EPS NQ rev (1m)1.83%
EPS NQ rev (3m)-5.21%
EPS NY rev (1m)-1.35%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.23
P/tB 10.23
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0
BVpS0.66
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.71%
ROE -130.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.89%
ROA(5y)N/A
ROE(3y)-170.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z 3.32
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.38%
EPS Next Y2.82%
EPS Next 2Y2.98%
EPS Next 3Y-0.51%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.01%
EBIT Next 3Y-24.03%
EBIT Next 5YN/A
FCF growth 1Y26.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.13%
OCF growth 3YN/A
OCF growth 5YN/A